Your browser doesn't support javascript.
loading
The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.
Saunders, Elizabeth C; McGovern, Mark P; Lambert-Harris, Chantal; Meier, Andrea; McLeman, Bethany; Xie, Haiyi.
Afiliação
  • Saunders EC; Dartmouth Psychiatric Research Center, Lebanon, New Hampshire.
  • McGovern MP; Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
  • Lambert-Harris C; Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
  • Meier A; Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
  • McLeman B; Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
  • Xie H; Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Am J Addict ; 24(8): 722-31, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26388539
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Previous research has been inconclusive about whether adding psychosocial treatment to medication assisted treatment (MAT) improves outcomes for patients with co-occurring psychiatric and opioid use disorders. This study evaluated the impact of MAT and psychosocial therapies on treatment outcomes for patients with co-occurring opioid use disorders and PTSD.

METHODS:

Patients meeting criteria for PTSD and substance use disorders were randomly assigned to one of three treatment conditions Standard Care (SC) alone, Integrated Cognitive Behavioral Therapy (ICBT) plus SC, or Individual Addiction Counseling (IAC) plus SC. Substance use and psychiatric symptoms were assessed at baseline and 6 months. Only patients with opioid use disorders were included in the present analyses (n = 126). Two-way ANOVAS and logistic regression analyses were used to examine associations between treatment conditions and MAT, for substance use and psychiatric outcomes.

RESULTS:

MAT patients receiving ICBT had significantly decreased odds of a positive urine drug screen, compared to non-MAT patients receiving SC alone (OR = .07, 95% CI = .01, .81, p = .03). For PTSD symptoms, a significant MAT by psychosocial treatment condition interaction demonstrated that MAT patients had comparable declines in PTSD symptoms regardless of psychosocial treatment type (F(2, 88) = 4.74, p = .011). Non-MAT patients in ICBT had significantly larger reductions in PTSD. CONCLUSIONS AND SCIENTIFIC

SIGNIFICANCE:

For patients with co-occurring opioid use disorders and PTSD, MAT plus ICBT is associated with more significant improvement in substance use. For non-MAT patients, ICBT is most beneficial for PTSD symptoms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Transtornos de Estresse Pós-Traumáticos / Terapia Cognitivo-Comportamental / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicotrópicos / Transtornos de Estresse Pós-Traumáticos / Terapia Cognitivo-Comportamental / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2015 Tipo de documento: Article